Literature DB >> 23650428

Cancer drugs in the United States: Justum Pretium--the just price.

Hagop M Kantarjian1, Tito Fojo, Michael Mathisen, Leonard A Zwelling.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23650428      PMCID： PMC3782152          DOI： 10.1200/JCO.2013.49.1845

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  33 in total

1.  The price of innovation: new estimates of drug development costs.

Authors:  Joseph A DiMasi; Ronald W Hansen; Henry G Grabowski
Journal:  J Health Econ       Date:  2003-03       Impact factor: 3.883

2.  The $64,000 question--what is a quality-adjusted life-year worth?

Authors:  Karen L Rascati
Journal:  Clin Ther       Date:  2006-07       Impact factor: 3.393

3.  DALYs and QALYs in developing countries.

Authors:  Victor Zarate
Journal:  Health Aff (Millwood)       Date:  2007 Jul-Aug       Impact factor: 6.301

4.  Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group.

Authors:  David M Dilts; Alan Sandler; Steven Cheng; Joshua Crites; Lori Ferranti; Amy Wu; Robert Gray; Jean MacDonald; Donna Marinucci; Robert Comis
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

5.  Cost control in a parallel universe: Medicare spending in the United States and Canada.

Authors:  David U Himmelstein; Steffie Woolhandler
Journal:  Arch Intern Med       Date:  2012-12-10

6.  Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Authors:  A Naing; H Veasey-Rodrigues; D S Hong; S Fu; G S Falchook; J J Wheler; A M Tsimberidou; S Wen; S N Fessahaye; E C Golden; J Aaron; M S Ewer; R Kurzrock
Journal:  Ann Oncol       Date:  2012-06-27       Impact factor: 32.976

7.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials.

Authors:  David M Dilts; Alan B Sandler
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Authors:  Bernard Escudier; Anna Pluzanska; Piotr Koralewski; Alain Ravaud; Sergio Bracarda; Cezary Szczylik; Christine Chevreau; Marek Filipek; Bohuslav Melichar; Emilio Bajetta; Vera Gorbunova; Jacques-Olivier Bay; Istvan Bodrogi; Agnieszka Jagiello-Gruszfeld; Nicola Moore
Journal:  Lancet       Date:  2007-12-22       Impact factor: 79.321

9.  Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Malcolm J Moore; David Goldstein; John Hamm; Arie Figer; Joel R Hecht; Steven Gallinger; Heather J Au; Pawel Murawa; David Walde; Robert A Wolff; Daniel Campos; Robert Lim; Keyue Ding; Gary Clark; Theodora Voskoglou-Nomikos; Mieke Ptasynski; Wendy Parulekar
Journal:  J Clin Oncol       Date:  2007-04-23       Impact factor: 44.544

10.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245
View more
  80 in total

1.  Do March-In Rights Ensure Access to Medical Products Arising From Federally Funded Research? A Qualitative Study.

Authors:  Carolyn L Treasure; Jerry Avorn; Aaron S Kesselheim
Journal:  Milbank Q       Date:  2015-12       Impact factor: 4.911

2.  Health Plans and Drug Companies Dip Their Toes Into Value-Based Pricing: The Pressure Is on P&T Committees to Monitor Utilization.

Authors:  Stephen Barlas
Journal:  P T       Date:  2016-01

3.  Health policy: Putting a price on cancer.

Authors:  Richard Sullivan; Ajay Aggarwal
Journal:  Nat Rev Clin Oncol       Date:  2016-02-09       Impact factor: 66.675

Review 4.  Cancer drug development: The missing links.

Authors:  Ajaikumar B Kunnumakkara; Devivasha Bordoloi; Bethsebie Lalduhsaki Sailo; Nand Kishor Roy; Krishan Kumar Thakur; Kishore Banik; Mehdi Shakibaei; Subash C Gupta; Bharat B Aggarwal
Journal:  Exp Biol Med (Maywood)       Date:  2019-04-08

Review 5.  The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective.

Authors:  Peter J Whitehouse
Journal:  Biochem Pharmacol       Date:  2013-12-01       Impact factor: 5.858

6.  Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patients.

Authors:  Alberto Farolfi; Corradina Della Luna; Angela Ragazzini; Elisa Carretta; Nicola Gentili; Carla Casadei; Michele Aquilina; Domenico Barone; Martina Minguzzi; Dino Amadori; Oriana Nanni; Giampaolo Gavelli
Journal:  Oncologist       Date:  2014-07-25

7.  Forecast for the Physician Payment Sunshine Act: partly to mostly cloudy?

Authors:  Stephanie R Morain; Charles Flexner; Nancy E Kass; Jeremy Sugarman
Journal:  Ann Intern Med       Date:  2014-12-16       Impact factor: 25.391

8.  New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?

Authors:  Pankaj Kumar Garg; Bhupendra Kumar Jain
Journal:  Oncologist       Date:  2014-12

9.  Cancer care burden: aiming at the Achilles heel.

Authors:  S Ahmed; R K Shahid; K Gesy
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

10.  Access to High Cost Cancer Medicines Through the Lens of an Australian Senate Inquiry-Defining the "Goods" at Stake.

Authors:  Narcyz Ghinea; Miles Little; Wendy Lipworth
Journal:  J Bioeth Inq       Date:  2017-07-18       Impact factor: 1.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.